# Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies

> **NCT04001517** · PHASE2 · COMPLETED · sponsor: **EIP Pharma Inc** · enrollment: 91 (actual)

## Conditions studied

- Dementia With Lewy Bodies (DLB)

## Interventions

- **DRUG:** Neflamapimod

## Key facts

- **NCT ID:** NCT04001517
- **Lead sponsor:** EIP Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-30
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2023-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04001517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04001517, "Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04001517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*